Etanercept Treatment in Ankylosing Spondylitis Hip Lesions.

Author: Young Chang KIM ¹ ; Sang Won MOON
Author Information

1. Department of Orthopaedic Surgery, Haeundae Paik Hospital, College of Medicine, Inje University, Busan, Korea. moonsw1106@gmail.com
Publication Type:Original Article
Keywords: Ankylosing spondylitis; Hip lesion; TNF antagonist; Etanercept
MeSH: Baths; Hip; Humans; Immunoglobulin G; Receptors, Tumor Necrosis Factor; Spondylitis, Ankylosing
From:Hip & Pelvis 2013;25(2):135-140
CountryRepublic of Korea
Language:Korean
Abstract: PURPOSE: To evaluate the efficacy of etanercept in patients with an ankylosing spondylitis hip lesion. MATERIALS AND METHODS: Between March 2008 and December 2011, this study evaluated 13 patients with hip lesions who were refractory to conventional therapy. The general improvement was evaluated by the Harris hip score, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), ESR, CRP, and complications. RESULTS: The mean Harris hip score changed from 55.6+/-3.4 to 87.2+/-4.3(P=0.01). The mean BASDAI/ BASFI decreased from 6.8+/-1.7/6.8+/-1.6 before treatment to 4.4+/-1.8(P=0.02)/4.3+/-1.1(P=0.02) after treatment. The mean ESR/CRP changed from 48.4+/-31.5/5.8+/-5.1 to 20.8+/-19.7(P=0.06)/3.1+/-4.2(P=0.03). No complications were encountered. CONCLUSION: These results suggest that etanercept can induce significant pain improvement in most ankylosing spondylitis hip lesions.